HC Wainwright Drops SLN to Neutral After 121% Weekly Surge

SLN shares have risen 121% in a week to $19.61, driven by clinical momentum and takeover speculation. HC Wainwright's response this morning was to cut its rating to Neutral and slash its price target 73%, from $75 to $20, within arm's reach of where the stock now trades.

The Analyst Reversal That Defines the Moment

Patrick Trucchio at HC Wainwright had reiterated a Buy with a $75 target as recently as June 2026. The same analyst now sees the stock fairly valued at $20. That 73% target cut, landing the day after a 121% weekly gain, is the sharpest compression in the analyst record for this name. The consensus sits at Hold, with two Buy ratings and three Holds and a mean target of $33.50. Even at the mean, that implies the stock is already trading more than 40% above the average bull view.

The backdrop is a potential takeover by Merck KGaA. ORTEX forecasts a 65% probability that SLN will be deleted from the MSCI World Small index, tied to that acquisition closing, with an estimated effective date of 5 February 2027 (dates are estimated, not confirmed by the index provider).

Options Market Reads It Differently

The put-call ratio jumped to 0.21 on 20 October, 3.3 standard deviations above its 20-day mean of 0.089. That is the highest PCR reading since the 52-week high of 0.52. The prior three weeks showed a PCR range of 0.056 to 0.067, so this is an abrupt shift. Some of that put activity may reflect holders locking in gains from the 121% move rather than directional bearish positioning, but the volume is notable regardless.

Cost to borrow has risen 82% over the past week to 0.97%. Availability has tightened to 267%, down from 774% a week ago. That is still a reasonably supplied lending market but the direction is clear: more shares are being borrowed as the stock runs. Short interest stands at 2.54 million shares, up 16.5% from a week earlier, though float data prevents a precise percentage calculation.

What the Register Shows

Richard Griffiths holds a Schedule 13D position at 7.97% of shares as last disclosed in August 2026, but has cut his stake sharply from a prior reported level of 21.7%. Tetragon Financial Group filed a fresh 13G/A on 13 October, reporting 5.3% of the class. Artal Group added 343,142 shares in the most recent period. Tetragon Financial Management built a new position of 2.79 million shares, last reported 5 October. These are as-last-disclosed figures and may not reflect current holdings.

The company reports next on 10 November 2026. The prior four earnings prints produced moves ranging from down 12.6% to up 23.2% on the day. With the stock already up 121% in a week, the size of that upcoming move window matters.

Data Summary

• Price: $19.61, up 121.1% over one week; peers up a median 4.7%
• Analyst: HC Wainwright downgraded to Neutral, target cut to $20 from $75; consensus mean target $33.50
• Options PCR: 0.21, 3.3 standard deviations above 20-day mean of 0.089
• Cost to borrow: 0.97%, up 82% week on week
• Availability: 267%, tightened from 774% a week ago
• Short interest: 2.54 million shares, up 16.5% in one week
• Index rebalance: ORTEX puts 65% probability on MSCI World Small deletion, estimated effective 5 February 2027
• Next earnings: 10 November 2026